Warburg Pincus affiliate sells 2.36% stake in Kalyan Jewellers for 5 mn

Warburg Pincus affiliate sells 2.36% stake in Kalyan Jewellers for $155 mn


Warburg, which first invested in Kalyan in 2014, held a 24.6% stake after the jeweller’s listing in March 2021.


A Warburg Pincus affiliate will sell 2.36% of its stake in Kalyan Jewellers for 13 billion rupees ($155 million) to another large stakeholder at a 2% discount to Wednesday’s closing price, the Indian company said.


The deal will see Highdell, the Warburg affiliate, sell over 24 million shares at 535 rupees each to Trikkur Sitarama Iyer Kalyanaraman, which currently holds 60.59% in the jeweller.


The U.S. private equity, through Highdell, held a 9.2% stake in Kalyan Jewellers as of the quarter ending June, as per BSE data.


Warburg, which first invested in Kalyan in 2014, held a 24.6% stake after the jeweller’s listing in March 2021.


Kalyan’s shares, which have risen nearly 54% so far this year, closed 0.5% higher on Wednesday.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

First Published: Aug 21 2024 | 6:04 PM IST



Source link

Nifty August futures trade at premium

Nifty August futures trade at premium


NSE India VIX dropped 3.52% to 13.33.

The Nifty August 2024 futures closed at 24,796.20, a premium of 26 points compared with the Nifty’s closing 24,770.20 in the cash market.

In the cash market, the Nifty 50 added 71.35 points or 0.29% to 24,770.20.

The NSE’s India VIX, a gauge of the market’s expectation of volatility over the near term, tumbled 3.52% to 13.33.

HDFC Bank, ICICI Bank and State Bank of India were the top traded individual stock futures contracts in F&O segment of NSE.

The August 2024 F&O contracts will expire on 29 August 2024.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Aug 21 2024 | 4:24 PM IST



Source link

Nifty August futures trade at premium

Sensex breaches 80k; Nifty above 24,750; VIX drops 3.52%


The domestic equity benchmarks ended with minor gains on Wednesday. The Nifty closed above the 24,750 mark after hitting the days low of 24,654.50 in early trade. Consumer durables, FMCG and media shares advanced while realty, PSU bank and bank shares declined.

As per provisional closing, the barometer index, the S&P BSE Sensex, gained 102.44 points or 0.13% to 80,905.30. The Nifty 50 index added 71.35 points or 0.29% to 24,770.20.

The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index added 0.43% and the S&P BSE Small-Cap index rose 0.87%.

The market breadth was strong. On the BSE, 2,611 shares rose and 1,340 shares fell. A total of 87 shares were unchanged.

The NSE’s India VIX, a gauge of the market’s expectation of volatility over the near term, tumbled 3.52% to 13.33.

IPO Update :

The initial public offer (IPO) of Orient Technologies received 3,91,69,656 bids for shares as against 74,49,846 shares on offer, according to stock exchange data at 15:25 IST on Wednesday (21 August 2024). The issue was subscribed 5.26 times.

The issue opened for bidding on Wednesday (21 August 2024) and it will close on Friday (23 August 2024). The price band of the IPO is fixed between Rs 195 to Rs 206 per share. An investor can bid for a minimum of 72 equity shares and in multiples thereof.

The initial public offer (IPO) of Interarch Building Products received 37,11,59,104 bids for shares as against 46,91,585 shares on offer, according to stock exchange data at 15:25 IST on Wednesday (21 August 2024). The issue was subscribed 79.11 times.

The issue opened for bidding on Monday (19 August 2024) and it will close on Wednesday (21 August 2024). The price band of the IPO is fixed between Rs 850 to Rs 900 per share. An investor can bid for a minimum of 16 equity shares and in multiples thereof.

Buzzing Index:

The Nifty Consumer Durables index added 1.47% to 40,671.15. The index rallied 6.43% in eight consecutive trading sessions.

Crompton Greaves Consumer Electricals (up 3.19%), Titan Company (up 2.45%), Havells India (up 1.65%), Voltas (up 1.21%), Cera Sanitaryware (up 1.13%), Dixon Technologies (India) (up 0.42%), V-Guard Industries (up 0.4%), Whirlpool of India (up 0.15%), Kajaria Ceramics (up 0.15%) and Bata India (up 0.1%) edged higher.

On the other hand, Amber Enterprises India (down 1.4%), Blue Star (down 0.15%) and Rajesh Exports (down 0.03%) declined.

Stocks in Spotlight:

Larsen & Toubro rose 0.59%. The EPC major announced that it has secured a large order for its Transportation Infrastructure Business for the integrated infrastructure development project in Navi Mumbai.

Meanwhile, the company informed that the Bombay High Court has quashed and set aside the show-cause notice and Rs 2,237-crore demand issued by the GST authorities.

Hindustan Zinc shed 0.35%. The company announced that it has received a GST demand notice amounting to Rs 26.12 crore from the Office of the Commissioner of Central Excise & CGST Commissionerate.

Exide Industries advanced 2.31% after the company said that it has invested Rs 74.99 crore in its wholly owned subsidiary, Exide Energy Solutions (EESL) by way of subscription to share capital on right basis.

Oriental Rail Infrastructure was locked in 5% upper circuit after the company reported consolidated net profit of Rs 4.37 crore in Q1 FY25 as compared with net loss of Rs 8.01 crore posted in Q1 FY24. Revenue from operations was at Rs 172.03 crore in first quarter of FY25, registering a growth of 42.91% as against Rs 120.37 crore posted a year ago.

Genus Power Infrastructures was locked in 5% upper circuit after the companys subsidiary secured three letters of award (LoAs) worth Rs 3,608.52 crore.

RMC switchgears was locked in 5% upper circuit after the companys subsidiary, RMC Green Energy secured approval from the Rajasthan Renewable Energy Corporation to establish a 50 megawatt (MW) renewable energy park in Rajasthan.

Indoco Remedies gained 4.84% after the firm received final approval from the US Food and Drug administration (USFDA) for its abbreviated new drug application (ANDA) for Lofexidine Tablets. Lofexidine Tablets is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment.

Global Markets:

European stocks advanced while most Asian stocks ended mixed on Wednesday, tracking a pullback on Wall Street and reflecting investor caution ahead of a key speech by Federal Reserve Chair Jerome Powell later this week.

The weakness in the U.S. market, where the Dow Jones Industrial Average closed down 0.15%, the S&P 500 fell 0.2%, and the Nasdaq Composite dropped 0.33%, spilled over into Asia.

Japan’s Nikkei index likely mirrored this cautiousness, as data revealed a smaller-than-expected export growth and a surge in imports, resulting in a trade deficit for July.

Hong Kong’s Hang Seng index was further pressured by a significant decline in e-commerce giant JD.com’s stock price. News reports suggesting Walmart’s planned sale of its stake in JD.com for $3.74 billion contributed to the 11% drop in JD stock.

Powered by Capital Market – Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Aug 21 2024 | 3:46 PM IST



Source link

Nykaa surges 19% on heavy volumes; stock at highest level since Oct 2022

Nykaa surges 19% on heavy volumes; stock at highest level since Oct 2022



Shares of FSN E-Commerce Ventures, the operator of beauty and personal care brand Nykaa, hit an over two-year high of Rs 228.50, as they surged 19 per cent on the BSE in Wednesday’s intra-day trade on the back of heavy volumes. The stock was trading at its highest level since October 3, 2022. It recorded its sharpest intra-day rally since November 11, 2022, when it zoomed nearly 20 per cent.


At 02:44 pm; Nykaa was trading 10 per cent higher at Rs 211.75, as compared to a flat trend in the BSE Sensex. The average trading volumes at the counter jumped over 10-fold. A combined 101.76 million equity shares representing 3.6 per cent of total equity of Nykaa changed hands on the NSE and BSE. The stock had hit a record high of Rs 429 on November 26, 2021.


FSN E-Commerce Ventures is involved in the manufacturing, selling, and distribution of beauty, wellness, fitness, personal care, health care, skin care, and hair care products. These products are sold through various channels, including online platforms such as e-commerce and m-commerce, as well as offline stores and stalls.


Last week, Nykaa reported 152 per cent year-on-year (YoY) jump in net profit of Rs 13.6 crore for the quarter ended June 30, 2024 (Q1FY25), compared to Rs 5.4 crore in the same period last year. The company’s operating revenue for the quarter was Rs 1,746 crore, up 23 per cent from Rs 1,422 crore in the corresponding quarter of the previous year.


The management is confident of accelerating growth going ahead, helped by the festive season. This means revenue growth momentum for the consolidated Beauty and Personal Care (BPC) business (including eB2B) may sustain towards 30 per cent-32 per cent YoY in the nearto-medium term.


While the recent demand environment has not been favourable, analysts at JM Financial Institutional Securities see Nykaa as the dominant player in a segment with strong secular tailwinds and expect sustained compounding returns.


While the brokerage firm said they have raised profitability estimates in omni-channel BPC and Fashion, they build in higher losses in eB2b+ International with cumulative losses of Rs 61.5 crore in FY25-28E before turning EBITDA profitable in FY29. “Rolling forward to September’25, we retain the target price at Rs 230 and reiterate ‘BUY’ rating, expecting the company to deliver robust numbers during the festive period this year,” analysts said in the result update.


Analyst at Elara Capital believe consolidation of Nykaa Man and the eB2B business in Nykaa BPC will positively impact revenue growth for the BPC business by 7-8 per cent. However, at an absolute EBITDA level, this impact could be offset by lower margins (losses in eB2B).


“We assume a margin expansion of 220 bps in the next two years for the consolidated BPC business after factoring in better ad revenue growth and lower losses in the eB2B business. But we largely maintain our FY26E/27E earnings estimates after factoring increased losses in the business, due to GCC. Break-even in the Fashion segment as per guidance and better growth offtake in BPC amidst threat of quick commerce players will drive share price performance,” the brokerage firm said in result update. However, the stock was currently trading above brokerage firm’s target price of Rs 210 per share.

 

 

First Published: Aug 21 2024 | 3:04 PM IST



Source link

Indoco Remedies stock soars over 5% on USFDA approval for opioids drug

Indoco Remedies stock soars over 5% on USFDA approval for opioids drug



Indoco Remedies stock surged up to 5.53 per cent at Rs 358.60 per share on the BSE in Wednesday’s intraday deals. This came after the company disclosed that it has received a final approval from the United States Food and Drugs Administration (USFDA) for its new drug application.


The Mumbai-based pharmaceutical received the top US regulator’s nod to market Lofexidine Tablets 0.18 mg, a generic equivalent of Lucemyra Tablets, 0.18 mg of the US-based drugmaker US WorldMeds.


This drug is indicated for mitigation of symptoms associated with acute withdrawal from opioids and for facilitation of the completion of opioid discontinuation treatment.




According to IQVIA Health data, the sales of the product are around $15.59 million with an expected growth of 38 per cent. 


“Indoco has been granted a competitive generic therapy (CGT) designation by the USFDA and being the first approved generic, is eligible for 180 days of CGT exclusivity for Lofexidine Tablets, 0.18 mg in the USA,” the company said in an exchange filing. 


The exclusivity will begin to run from the date of the first commercial marketing of the product. Indoco intends to launch the product immediately in the USA.


This product will be manufactured by Indoco at its manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa – 403722 in India.


 “We are extremely pleased with this development as this strengthens our position in the US market, driving us closer to expanding our reach in the US,” said Aditi Panandikar, Managing Director, Indoco Remedies.  


Indoco Remedies has a total market capitalisation of Rs 3,227.30 crore. Its shares are trading at a price to earnings multiple of 61.44 times with an earning per share of Rs 11.46. 


The share price of the company has dropped 10 per cent year to date, while it has gained only 6.5 per cent in the last one year.


At 01:32 PM; the stock of the company was trading 4.59 per cent higher at Rs 350.80 per share on the BSE. By comparison, the BSE Sensex was nearly flat, down 0.10 per cent at 80,719 levels.


Headquartered in Mumbai, Indoco has operations in 55 countries. The company is involved in the manufacturing and marketing of pharmaceutical formulations (finished dosage forms) and active pharmaceutical ingredients (APIs).

First Published: Aug 21 2024 | 1:39 PM IST



Source link

Updater Services stock surges 11% on acquiring stake in subsidiary; details

Updater Services stock surges 11% on acquiring stake in subsidiary; details



Updater Services shares surged up to 10.6 per cent at Rs 358.60 per share on the BSE in Wednesday’s intraday deals. This came after the company acquired an additional 22.3 per cent stake in Denave India for Rs 52.57 crore on Tuesday.


“The company has increased the investment in Denave India, material subsidiary company from 67.27 per cent to 89.57 per cent by acquiring 37,48,614 equity shares from its promoters and other shareholders,” the company said in an exchange filing.


Another subsidiary of Updater Services, Matrix Business Services holds 10.43 per cent in Denave. Further to the acquisition, the post shareholding percentage in Denave of the company along with its subsidiary now stands at 100 per cent.


As of 31 March 2024, Denave India Private Limited reported a consolidated turnover of Rs. 454.28 crore. The company’s consolidated profit after tax (PAT) stood at Rs. 20.23 crore. 


Over the past three years, Denave India’s consolidated turnover has increased significantly. For the financial year 2021-22 (FY22), the turnover was Rs. 2,64.86 crore. In FY 22-23, it rose to Rs. 3,64.22 crore, marking an increase of approximately 37.6 per cent. For FY 23-24, the turnover further grew to Rs. 454.28 crore, representing a 24.8 per cent rise from the previous year.


Denave India Private Ltd, incorporated on 12th January 1999, is currently engaged in sales enablement as well as various support and staffing services.


Updater Services has a total market capitalisation of Rs 2,382.36 crore. Its shares are trading at a price to earnings multiple of 61.44 times with an earning per share of Rs 5.27. 


The share price of the company has zoomed 9.2 per cent year to date, while it has gained 25.4 per cent in the last one year.


At 12:59 PM; the stock of the company was trading 9.71 per cent higher at Rs 355.45 per share on the BSE. By comparison, the BSE Sensex was nearly flat, down 0.07 per cent at 80,746 levels. 


Updater Services is an integrated business services platform in India, providing both integrated facilities management (IFM) and business support services (BSS) with a nationwide presence. Within the BSS segment, the company offers audit and assurance services through its subsidiary, Matrix.

The company’s service portfolio encompasses various sectors, including FMCG manufacturing, engineering, BFSI, healthcare, IT, automobiles, logistics and warehousing, airports, ports, infrastructure, and retail, among others.

First Published: Aug 21 2024 | 1:10 PM IST



Source link

YouTube
Instagram
WhatsApp